. 2010 Aug 17;2:101–119. doi: 10.2147/DHPS.S6317

Table 8.

The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination abatacept and methotrexate or alternative DMARD compared to DMARD alone

	AIM44		Kremer et al45		ATTAIN46
	MTX + placebo n = 219	MTX + abatacept 10 mg/kg 4 weekly n = 433	MTX + placebo n = 119	MTX + abatacept 10 mg/kg 4 weekly n = 115	DMARD + placebo n = 133	DMARD + abatacept 10 mg/kg 4 weekly n = 258
At 6 months (%):
ACR 20					20	50^a
ACR 50					4	20^a
ACR 70					2	10
At 12 months (%):
ACR 20	40	73^a	36	63^a
ACR 50	18	48^a	20	42^a
ACR 70	6	29^a	8	21

Note:

P < 0.001 compared to placebo group.

Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate.